Results 211 to 220 of about 93,364 (304)

Hormonal replacement therapy in postmenopausal women ≥50 years is associated with the incidence of glaucoma: Evidence from 6576 females in Finland

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose Hormonal replacement therapy (HRT) in postmenopausal women appears to affect glaucoma risk, but findings are inconsistent. We aimed to explore whether the use of postmenopausal HRT plays a role in glaucoma development in Finland. Methods The main outcome variable was glaucoma incidence measured by initiation of special reimbursement ...
Sirpa Loukovaara, Jari Haukka
wiley   +1 more source

Genetic risk factors in Finnish patients with Fuchs endothelial corneal dystrophy

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To study the genetic risk factors of Fuchs endothelial corneal dystrophy (FECD) in the Finnish population using hospital‐based and large biobank cohorts. Methods We genotyped a cohort of 107 Finnish patients with FECD for the primary associated genetic risk factor, the TCF4 (CTG)>50 expansion, and studied their clinical phenotype.
Inka‐Tuulevi Vähämäki   +10 more
wiley   +1 more source

International Delphi consensus on feminising genital surgery in assigned‐male‐at‐birth individuals

open access: yesBJU International, EarlyView.
Objective To achieve an international expert consensus among surgeons on the indications, contraindications, and perioperative management of feminising genital surgery (FGS) for assigned‐male‐at‐birth (AMAB) individuals, using a Delphi process. Methods A two‐round on‐line Delphi survey (May–July 2025) followed by a final consensus meeting (September ...
Marta Pezzoli   +30 more
wiley   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

The future of HRT/MHT and Alzheimer's disease risk, onset and progression. [PDF]

open access: yesJ Prev Alzheimers Dis
Lephart ED   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy